Abstract Introduction GLP-1 receptor agonists (GLP1-RAs) are increasingly prescribed as an alternative to bariatric surgery for weight loss, and may pose as an alternative to conversion Roux-En-Y Gastric Bypass (cRYGB) in patients with insufficient weight loss or weight recurrence after sleeve gastrectomy [A C, N C, A I
Current Status (2026) Retatrutide remains under clinical investigation and is progressing through large Phase 3 trials for obesity and related metabolic conditions
This condition causes hair follicles to enter the resting phase earlier than normal, resulting in increased shedding
Studies have demonstrated that the latest basal analogues may cause less hypoglycaemia than first-generation basal analogues and NPH insulin, while rapid-acting analogues achieve better mealtime coverage and less postprandial hypoglycaemia than short-acting (regular) human insulin
There are a few specific groups who should exercise caution
GLP-1 primarily reduces appetite and slows gastric emptying, GIP enhances fat metabolism and insulin sensitivity, and glucagon increases energy expenditure and fat oxidation
